Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia
These findings provide real-world evidence further supporting the use of oral-AZA as a standard-of-care maintenance therapy in current routine clinical practice for patients with AML in remission who do not receive hematopoietic stem cell transplantation. These results may inform a broader clinical audience because of the inclusion of patients with diverse demographic and clinical characteristics.
Authors
- Keith L. Davis (ORCID: https://orcid.org/0000-0002-0044-7107)
- Andre C. Schuh (ORCID: https://orcid.org/0000-0003-2869-852X)
- Felio Bello (ORCID: https://orcid.org/0000-0003-1459-0278)
- Maria Strocchia
- Yeran Li (ORCID: https://orcid.org/0000-0002-9777-7152)
- Brian F. Leber (ORCID: https://orcid.org/0000-0001-5502-1480)
- Marcia T. Ruiz
- Rohan Parikh (ORCID: https://orcid.org/0000-0003-4516-9996)
- Thomas Prébet (ORCID: https://orcid.org/0000-0002-6872-625X)
- Filippa Pettersson
- Jan Sieluk (ORCID: https://orcid.org/0000-0002-1833-0273)
- Siddhi Korgaonkar (ORCID: https://orcid.org/0009-0007-3351-3901)
- Lona Gaugler
- Carlos E. Vigil (ORCID: https://orcid.org/0000-0002-7085-0479)
- Hala El‐Gendy
Institutions
- University Health Network (CA)
- Bristol-Myers Squibb (United States) (US)
- RTI Health Solutions (US)
- McMaster University (CA)
Publication Details
- Journal
- Cancer
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1002/cncr.35845
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Bristol-Myers Squibb